BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37348499)

  • 1. Tumor and local lymphoid tissue interaction determines prognosis in high-grade serous ovarian cancer.
    Lu H; Lou H; Wengert G; Paudel R; Patel N; Desai S; Crum B; Linton-Reid K; Chen M; Li D; Ip J; Mauri F; Pinato DJ; Rockall A; Copley SJ; Ghaem-Maghami S; Aboagye EO
    Cell Rep Med; 2023 Jul; 4(7):101092. PubMed ID: 37348499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
    Zhang K; Xie X; Zou LH; Guo SQ
    Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
    Kasikova L; Rakova J; Hensler M; Lanickova T; Tomankova J; Pasulka J; Drozenova J; Mojzisova K; Fialova A; Vosahlikova S; Laco J; Ryska A; Dundr P; Kocian R; Brtnicky T; Skapa P; Capkova L; Kovar M; Prochazka J; Praznovec I; Koblizek V; Taskova A; Tanaka H; Lischke R; Mendez FC; Vachtenheim J; Heinzelmann-Schwarz V; Jacob F; McNeish IA; Halaska MJ; Rob L; Cibula D; Orsulic S; Galluzzi L; Spisek R; Fucikova J
    Nat Commun; 2024 Mar; 15(1):2528. PubMed ID: 38514660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
    Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
    BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
    He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a risk score model based on tertiary lymphoid structure-related genes for predicting immunotherapy efficacy in non-small cell lung cancer.
    Mei SQ; Liu JQ; Huang ZJ; Luo WC; Peng YL; Chen ZH; Deng Y; Xu CR; Zhou Q
    Thorac Cancer; 2024 May; 15(14):1119-1131. PubMed ID: 38558529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
    Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
    Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of prognostic gene signature for basal-like breast cancer and high-grade serous ovarian cancer.
    Zhang Y; Liu J; Raj-Kumar PK; Sturtz LA; Praveen-Kumar A; Yang HH; Lee MP; Fantacone-Campbell JL; Hooke JA; Kovatich AJ; Shriver CD; Hu H
    Breast Cancer Res Treat; 2020 Dec; 184(3):689-698. PubMed ID: 32880016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer.
    Lo Riso P; Villa CE; Gasparoni G; Vingiani A; Luongo R; Manfredi A; Jungmann A; Bertolotti A; Borgo F; Garbi A; Lupia M; Laise P; Das V; Pruneri G; Viale G; Colombo N; Manzo T; Nezi L; Cavallaro U; Cacchiarelli D; Walter J; Testa G
    Genome Med; 2020 Oct; 12(1):94. PubMed ID: 33121525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
    Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1, Ki67, and β-Catenin Immunoexpression Is Not Related to Differentiation, Platinum Response, or Prognosis in Women With Low- and High-Grade Serous Ovarian Carcinoma.
    Sallum LF; Andrade L; Bastos Eloy da Costa L; Ramalho S; Ferracini AC; Natal RA; Brito ABC; Sarian LO; Derchain S
    Int J Gynecol Cancer; 2018 Mar; 28(3):437-447. PubMed ID: 29465506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of the 1p34.3 risk locus implicates GNL2 in high-grade serous ovarian cancer.
    Nakamura K; Reid BM; Chen A; Chen Z; Goode EL; Permuth JB; Teer JK; Tyrer J; Yu X; Kanetsky PA; Pharoah PD; Gayther SA; Sellers TA; Lawrenson K; Karreth FA
    Am J Hum Genet; 2022 Jan; 109(1):116-135. PubMed ID: 34965383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients.
    Germain C; Devi-Marulkar P; Knockaert S; Biton J; Kaplon H; Letaïef L; Goc J; Seguin-Givelet A; Gossot D; Girard N; Validire P; Lefèvre M; Damotte D; Alifano M; Lemoine FM; Steele KE; Teillaud JL; Hammond SA; Dieu-Nosjean MC
    Front Immunol; 2021; 12():626776. PubMed ID: 33763071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex serum immune profiling reveals circulating LAG-3 is associated with improved patient survival in high grade serous ovarian cancer.
    Eurich K; De La Cruz P; Laguna A; Woodman M; McAdams J; Lips E; Ebott J; DiSilvestro J; Ribeiro J; James N
    Gynecol Oncol; 2023 Jul; 174():200-207. PubMed ID: 37224792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.
    Xu AM; Haro M; Walts AE; Hu Y; John J; Karlan BY; Merchant A; Orsulic S
    Sci Adv; 2024 Apr; 10(16):eadk8805. PubMed ID: 38630822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
    Ukita M; Hamanishi J; Yoshitomi H; Yamanoi K; Takamatsu S; Ueda A; Suzuki H; Hosoe Y; Furutake Y; Taki M; Abiko K; Yamaguchi K; Nakai H; Baba T; Matsumura N; Yoshizawa A; Ueno H; Mandai M
    JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35552285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.
    Jin C; Xue Y; Li Y; Bu H; Yu H; Zhang T; Zhang Z; Yan S; Lu N; Kong B
    Int J Gynecol Cancer; 2018 Jan; 28(1):51-58. PubMed ID: 28976449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.